The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Gottesman L

The Virus, the Tinkerer, and the Matrix: A Cautionary Tale.

Diseases of the colon and rectum. 2023;66(3):352-354

Gendarme S, Pastré J, Billaud EM, Gibault L, Guillemain R, Oudard S, Medioni J, Lillo-Lelouet A, Israël-Biet D

Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients.

Therapie. 2023;78(3):267-278

Murakami Y, Fujita T, Wakatabe Y, Iwamura M

A Fatal Case of Life-Threatening Interstitial Pneumonitis Induced by Everolimus for Metastatic Renal Cell Carcinoma: A Comment about the Increased Risk of Interstitial Lung Disease in Japanese.

Case reports in urology. 2019;2019:2703871

Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J

mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.

International journal of cancer. 2016;138(10):2312-21

Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH

Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.

The oncologist. 2015;20(9):1077-83

Duran I, Goebell PJ, Papazisis K, Ravaud A, Weichhart T, Rodriguez-Portal JA, Budde K

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.

Expert opinion on drug safety. 2014;13(3):361-72

Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.

BJU international. 2014;113(3):376-82

Molas-Ferrer G, Soy-Muner D, Anglada-Martínez H, Riu-Viladoms G, Estefanell-Tejero A, Ribas-Sala J

Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2013;33(3):297-300

Willemsen AE, van Herpen CM

mTOR inhibitor-related pulmonary toxicity; incidence even higher.

Acta oncologica (Stockholm, Sweden). 2013;52(6):1234

Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.

Acta oncologica (Stockholm, Sweden). 2012;51(7):873-9

Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(8):1943-1953

Sola E, Lopez V, Burgos D, Cabello M, Gutierrez C, Martin A, Peña M, Gonzalez-Molina M

Pulmonary toxicity associated with sirolimus treatment in kidney transplantation.

Transplantation proceedings. 2006;38(8):2438-40